In addition, a double-blind placebo study using arimoclomol in ALS patients with SOD1 mutants showed that the therapeutic effects were not detected at a statistically significant level, although the treatment was potentially effective for ALS patients with several mutations (Benatar, et al., 2018). This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.